Amendments to the Claims:

Claims 1-5 (Canceled)

6. (Currently Amended) A transgenic mouse whose genome comprises a null ~~homozygous disruption in the~~ FPR-RS4 ~~gene~~allele, wherein the null allele comprises exogenous DNA~~transgenic mouse exhibits, relative to a wild-type mouse, a phenotypic abnormality selected from the group consisting of increased anxiety, decreased coordination, impaired balance and decreased susceptibility to seizure~~.

Claim 7 (Canceled)

8. (Previously Presented) A cell derived from the transgenic mouse of claim 6.
9. (Currently amended) A method of producing a transgenic mouse of claim 6~~whose genome comprises a homozygous disruption in the FPR-RS4 gene~~, the method comprising:
   (a) introducing a construct that targets the FPR-RS4 gene into a mouse embryonic stem cell;
   (b) introducing the embryonic stem cell into a blastocyst;
   (c) implanting the resulting blastocyst into a pseudopregnant mouse, wherein said pseudopregnant mouse gives birth to a chimeric mouse; and
   (d) breeding the chimeric mouse to produce the transgenic mouse~~, wherein the transgenic mouse exhibits, relative to a wild-type mouse, a phenotypic abnormality selected from the group consisting of increased anxiety, decreased coordination and decreased susceptibility to seizure~~.

Claims 10-34 (Canceled)

35. (Currently amended) The transgenic mouse of claim 4~~2~~6, wherein the increased anxiety is characterized by decreased time spent in a central region during an open field test.
36. (Currently amended) The transgenic mouse of claim 4~~2~~6, wherein the decreased coordination is characterized by decreased time to fall during a rotarod test.
37. (Currently amended) The transgenic mouse of claim 4~~2~~6, wherein the decreased coordination is characterized by a decrease in time to fall off the accelerating rotarod.
38. (Currently amended) The transgenic mouse of claim 4~~2~~6, wherein the decreased coordination comprises impaired motor coordination, impaired balance, or ataxia.

39. (Currently amended) The transgenic mouse of claim 426, wherein the decreased susceptibility to seizure is characterized by an increased dose of metrazol to reach seizure.
40. (New) The transgenic mouse of claim 6 wherein said mouse is heterozygous for said null allele.
41. (New) The transgenic mouse of claim 6 wherein said mouse is homozygous for said null allele.
42. (New) The transgenic mouse of claim 6 wherein said mouse exhibits, relative to a wild-type control mouse, a phenotype selected from the group consisting of increased anxiety, decreased coordination, impaired balance and decreased susceptibility to seizure
43. (New) The transgenic mouse of claim 6 wherein said FPR-RS4 comprises the sequence of SEQ ID NO:1.
44. (New) The transgenic mouse of claim 6 wherein said exogenous DNA encodes a selection marker.
45. (New) The transgenic mouse of claim 44 wherein said selection marker is a neomycin resistance gene.
46. (New) The transgenic mouse of claim 6 wherein said exogenous DNA encodes a visible marker.
47. (New) The transgenic mouse of claim 46 wherein said visible marker is lacZ.